Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
Xeljanz FDA Drug Safety Communication in February 2021 Puts Heightened Scrutiny on Pfizer
One wonders how the FDA might react to this continued “direct to consumer” advertising for Xeljanz which Pfizer is (still) sponsoring after the February 2021 FDA Xeljanz Drug Safety Communication about Xeljanz causing heart…
-
Drug Safety Issue for Stelara: Severe Cardiovascular Events Soon After Initiation of Stelara Treatment
Stelara-Associated Acute Coronary Syndrome, Stroke, and Unstable Angina Seen in Recent Stelara French Medical Study (Posted by Tom Lamb at DrugInjuryWatch.com) Stelara (ustekinumab) was approved by the FDA in 2009, initially for…
-
Vascular Endothelial Growth Factor (VEGF) Inhibitors: Increased Risk Of Aneurysm And Artery Dissection
New Warnings Added To Drug Labels For All VEGF Inhibitors By UK's MHRA Already; FDA Is Evaluating Need For Regulatory Action (Posted by Tom Lamb at DrugInjuryWatch.com) On July 31, 2020 the…
-
Lemtrada ANCA-Associated Systemic Vasculitis Case Report Presented In Recent Medical Journal Article
Lemtrada Side Effects Range From Drug-Induced Autoimmune Complications To Cardiovascular Reactions (Posted by Tom Lamb at DrugInjuryWatch.com) Medical researchers in Switzerland recently presented the case of a 26-year-old man who developed life-threatening…
-
Lemtrada Cardiovascular Reactions Can Occur Within 1-3 Days Of Infusions In People Without Any Identifiable Risk Factors
Unpredictable And Potentially Fatal Immune-Mediated Reactions Can Occur Within Months And Up To At Least 4 Years After Lemtrada Treatments (Posted by Tom Lamb at DrugInjuryWatch.com) The UK Medicines and Healthcare Products…
-
Hypophosphatemia As A Side Effect Of Injectafer vs. Monoferric Treatments: Comparisons From Two Clinical Trials
New JAMA Medical Journal Article Reports A Significant Higher Hypophosphatemia Incidence Rate With Injectafer Compared To Monoferric (Posted by Tom Lamb at DrugInjuryWatch.com) In this earlier article, “Injectafer-Induced Hypophosphatemia Can Be A…
-
Injectafer-Induced Hypophosphatemia Can Be A Serious Side Effect Of This Iron Deficiency Anemia Drug
Hypophosphatemia Is An Injectafer Side Effect With Possible Medical Complications Leading To Hospitalization Or Death (Posted by Tom Lamb at DrugInjuryWatch.com) Injectafer (ferric carboxymaltose) is an iron replacement injection approved by the…
-
Hemophilia Drug Hemlibra: Adverse Events Reports And Patient Deaths Raise Some Concerns
November 2019 NEJM Letter Points Out Possible Public Health Issue For Hemlibra Used By Hemophilia A Patients (Posted by Tom Lamb at DrugInjuryWatch.com) We recently learned about drug safety issues involving Hemlibra…